Senescence: An antiviral defense that is tumor suppressive?

Carcinogenesis

Volumn 31, Issue 1, 2009, Pages 19-26

  Reddel, Roger R ^a,b  

^a CHILDREN'S MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; B RAF KINASE; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYTOTOXIC AGENT; DYSKERIN; HIGH MOBILITY GROUP A PROTEIN; HISTONE H2AX; INTERCELLULAR ADHESION MOLECULE 1; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MRE11 PROTEIN; NATURAL KILLER CELL RECEPTOR NKG2D; NIBRIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN P53; RAD50 PROTEIN; RETINOBLASTOMA PROTEIN; STROMELYSIN; TELOMERASE REVERSE TRANSCRIPTASE; TELOMERASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; CANCER INHIBITION; CARCINOGENESIS; CELL AGING; CELL CYCLE ARREST; CELL PROLIFERATION; DRUG RESPONSE; GENE ACTIVATION; HEPATITIS B VIRUS; HOST RESISTANCE; HUMAN; INNATE IMMUNITY; LYMPHOMA; NEVUS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; SENESCENCE; SIGNAL TRANSDUCTION; TELOMERE; TUMOR IMMUNITY; TUMOR SUPPRESSOR GENE; VIRUS IMMUNITY; ENZYMOLOGY; IMMUNOLOGY; METABOLISM; NEOPLASM; PATHOLOGY; REVIEW;

CELL AGING; CELL PROLIFERATION; HUMANS; NEOPLASMS; PHENOTYPE; TELOMERASE;

EID: 74049124577     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp274     Document Type: Article

References (151)

1. Reddel, R.R. (2000) The role of senescence and immortalization in carcinogenesis. Carcinogenesis, 21, 477-484.
2. Sasaki, M. et al. (2001) Senescent cells are resistant to death despite low Bcl-2 level. Mech. Ageing Dev., 122, 1695-1706.
3. Hayflick, L. et al. (1961) The serial cultivation of human diploid cell strains. Exp. Cell Res., 25, 585-621.
4. Cristofalo, V.J. et al. (1993) Replicative senescence of human fibroblast-like cells in culture. Physiol. Rev., 73, 617-638.
5. Berube, N.G. et al. (1998) The genetics of cellular senescence. Am. J. Hum. Genet., 62, 1015-1019.
6. Maier, A.B. et al. (2009) Relation between replicative senescence of human fibroblasts and life history characteristics. Ageing Res. Rev., 8, 237-243.
7. Lundberg, A.S. et al. (2000) Genes involved in senescence and immortalization. Curr. Opin. Cell Biol., 12, 705-709.
8. Goldstein, S. et al. (1994) Overexpression of plasminogen activator inhibitor type-1 in senescent fibroblasts from normal subjects and those with Werner syndrome. J. Cell. Physiol., 161, 571-579.
9. Alcorta, D.A. et al. (1996) Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc. Natl Acad. Sci. USA, 93, 13742-13747.
10. Wong, H. et al. (1996) Differential CDK-inhibitor gene expression in aging human diploid fibroblasts. Exp. Gerontol., 31, 311-325.
11. He, L. et al. (2007) A microRNA component of the p53 tumour suppressor network. Nature, 447, 1130-1134.
12. Dimri, G.P. et al. (1995) A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl Acad. Sci. USA, 92, 9363-9367.
13. Severino, J. et al. (2000) Is β-galactosidase staining a marker of senescence in vitro and in vivo? Exp. Cell Res., 257, 162-171.
14. d'Adda di Fagagna, F. et al. (2003) A DNA damage checkpoint response in telomere-initiated senescence. Nature, 426, 194-198.
15. Narita, M. et al. (2003) Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell, 113, 703-716.
16. Adams, P.D. (2007) Remodeling chromatin for senescence. Aging Cell, 6, 425-427.
17. Banumathy, G. et al. (2009) Human UBN1 is an ortholog of yeast Hpc2p and has an essential role in the HIRA/ASF1a chromatin-remodeling pathway in senescent cells. Mol. Cell. Biol., 29, 758-770.
18. Funayama, R. et al. (2007) Cellular senescence and chromatin structure. Chromosoma, 116, 431-440.
19. Mimura, T. et al. (2006) Replication competence and senescence in central and peripheral human corneal endothelium. Invest. Ophthalmol. Vis. Sci., 47, 1387-1396.
20. Martin, J.A. et al. (2001) Telomere erosion and senescence in human articular cartilage chondrocytes. J. Gerontol. A Biol. Sci. Med. Sci., 56, B172-B179.
21. Going, J.J. et al. (2001) 'Senescence-associated' β-galactosidase activity in the upper gastrointestinal tract. J. Pathol., 196, 394-400.
22. Herbig, U. et al. (2006) Cellular senescence in aging primates. Science, 311, 1257.
23. Jeyapalan, J.C. et al. (2007) Accumulation of senescent cells in mitotic tissue of aging primates. Mech. Ageing Dev., 128, 36-44.
24. Itahana, K. et al. (2004) Mechanisms of cellular senescence in human and mouse cells. Biogerontology, 5, 1-10.
25. Collado, M. et al. (2005) Tumour biology: senescence in premalignant tumours. Nature, 436, 642.
26. Chen, Z. et al. (2005) Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature, 436, 725-730.
27. Braig, M. et al. (2005) Oncogene-induced senescence as an initial barrier in lymphoma development. Nature, 436, 660-665.
28. Michaloglou, C. et al. (2005) BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature, 436, 720-724.
29. Raulet, D.H. et al. (2009) Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat. Rev. Immunol., 9, 568-580.
30. Xue, W. et al. (2007) Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature, 445, 656-660.
31. Krizhanovsky, V. et al. (2008) Senescence of activated stellate cells limits liver fibrosis. Cell, 134, 657-667.
32. Hanahan, D. et al. (2000) The hallmarks of cancer. Cell, 100, 57-70.
33. Sager, R. (1991) Senescence as a mode of tumor suppression. Environ. Health Perspect., 93, 59-62.
34. Smith, J.R. et al. (1996) Replicative senescence: implications for in vivo aging and tumor suppression. Science, 273, 63-67.
35. Campisi, J. (1997) Aging and cancer: the double-edged sword of replicative senescence. J. Am. Geriatr. Soc., 45, 482-488.
36. Mathon, N.F. et al. (2001) Cell senescence and cancer. Nat. Rev. Cancer, 1, 203-213.
37. Ishikawa, F. (2003) Cellular senescence, an unpopular yet trustworthy tumor suppressor mechanism. Cancer Sci., 94, 944-947.
38. Prieur, A. et al. (2008) Cellular senescence in vivo: a barrier to tumorigenesis. Curr. Opin. Cell Biol., 20, 150-155.
39. Schmitt, C.A. et al. (2002) A senescence program controlled by p53 and p16(INK4a) contributes to the outcome of cancer therapy. Cell, 109, 335-346.
40. Krtolica, A. et al. (2001) Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc. Natl Acad. Sci. USA, 98, 12072-12077.
41. Rodier, F. et al. (2009) Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat. Cell Biol., 11, 973-979.
42. Kuilman, T. et al. (2008) Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell, 133, 1019-1031.
43. Acosta, J.C. et al. (2008) Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell, 133, 1006-1018.
44. Parrinello, S. et al. (2005) Stromal-epithelial interactions in aging and cancer: senescent fibroblasts alter epithelial cell differentiation. J. Cell Sci., 118, 485-496.
45. Coppe, J.P. et al. (2006) Secretion of vascular endothelial growth factor by primary human fibroblasts at senescence. J. Biol. Chem., 281, 29568-29574.
46. Artandi, S.E. et al. (2000) A critical role for telomeres in suppressing and facilitating carcinogenesis. Curr. Opin. Genet. Dev., 10, 39-46.
47. Campisi, J. (2001) Cellular senescence as a tumor-suppressor mechanism. Trends Cell Biol., 11, S27-S31.
48. Campisi, J. (2007) Cellular senescence: when bad things happen to good cells. Nat. Rev. Mol. Cell Biol., 8, 729-740.
49. Collado, M. et al. (2006) The power and the promise of oncogene-induced senescence markers. Nat. Rev. Cancer, 6, 472-476.
50. Moiseeva, O. et al. (2006) DNA damage signaling and p53-dependent senescence after prolonged β-interferon stimulation. Mol. Biol. Cell, 17, 1583-1592.
51. Sugden, B. (1989) An intricate route to immortality. Cell, 57, 5-7.
52. DiPaolo, J.A. et al. (1993) Cellular and molecular alterations in human epithelial cells transformed by recombinant human papillomavirus DNA. Crit. Rev. Oncog., 4, 337-360.
53. Bryan, T.M. et al. (1994) SV40-induced immortalization of human cells. Crit. Rev. Oncog., 5, 331-357.
54. Oishi, N. et al. (2007) Hepatitis B virus X protein overcomes oncogenic RAS-induced senescence in human immortalized cells. Cancer Sci., 98, 1540-1548.
55. Munoz-Fontela, C. et al. (2007) Control of virus infection by tumour suppressors. Carcinogenesis, 28, 1140-1144.
56. Ferbeyre, G. (2002) PML a target of translocations in APL is a regulator of cellular senescence. Leukemia, 16, 1918-1926.
57. Girardi, A.J. et al. (1965) SV40-induced transformation of human diploid cells: crisis and recovery. J. Cell. Comp. Physiol., 65, 69-84.
58. Counter, C.M. et al. (1992) Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J., 11, 1921-1929.
59. Wright, W.E. et al. (1989) Reversible cellular senescence: implications for immortalization of normal human diploid fibroblasts. Mol. Cell. Biol., 9, 3088-3092.
60. Rubelj, I. et al. (1997) Loss of T-antigen sequences allows SV40-transformed human cells in crisis to acquire a senescent-like phenotype. J. Gerontol. A Biol. Sci. Med. Sci., 52A, B229-B234.
61. Huschtscha, L.I. et al. (1983) Limited and unlimited growth of SV40-transformed cells from human diploid MRC-5 fibroblasts. J. Cell Sci., 63, 77-99.
62. Colgin, L.M. et al. (1999) Telomere maintenance mechanisms and cellular immortalization. Curr. Opin. Genet. Dev., 9, 97-103.
63. INK4 expression and telomere length during spontaneous immortalization of Li-Fraumeni syndrome fibroblasts. Mol. Cell. Biol., 15, 4745-4753.
64. CIP1/WAF1 gene in normal diploid human fibroblasts. Science, 277, 831-834.
65. INK4 expression. Oncogene, 13, 1259-1268.
66. INK4 expression by methylation is associated with lifespan extension of human mammary epithelial cells. Cancer Res., 58, 3508-3512.
67. Stampfer, M.R. (1985) Isolation and growth of human mammary epithelial cells. J. Tissue Cult. Methods, 9, 107-115.
68. Reddel, R.R. (1998) A reassessment of the telomere hypothesis of senescence. BioEssays, 20, 977-984.
69. Fridman, A.L. et al. (2008) Critical pathways in cellular senescence and immortalization revealed by gene expression profiling. Oncogene, 27, 5975-5987.
70. Noda, A. et al. (1994) Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp. Cell Res., 211, 90-98.
71. Smith, J.R. et al. (1996) Studies demonstrating the complexity of regulation and action of the growth inhibitory gene SDI1. Exp. Gerontol., 31, 327-335.
72. Fujita, K. et al. (2009) p53 isoforms Δ133p53 and p53β are endogenous regulators of replicative cellular senescence. Nat. Cell Biol., 11, 1135-1142.
73. Dumble, M. et al. (2004) Insights into aging obtained from p53 mutant mouse models. Ann. N. Y. Acad. Sci., 1019, 171-177.
74. Hinkal, G.W. et al. (2009) Altered senescence, apoptosis, and DNA damage response in a mutant p53 model of accelerated aging. Mech. Ageing Dev., 130, 262-271.
75. Keyes, W.M. et al. (2005) p63 deficiency activates a program of cellular senescence and leads to accelerated aging. Genes Dev., 19, 1986-1999.
76. Sommer, M. et al. (2006) ΔNp63α overexpression induces downregulation of Sirt1 and an accelerated aging phenotype in the mouse. Cell Cycle, 5, 2005-2011.
77. Narita, M. et al. (2006) A novel role for high-mobility group A proteins in cellular senescence and heterochromatin formation. Cell, 126, 503-514.
78. Ruas, M. et al. (1998) The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim. Biophys. Acta, 1378, F115-F177.
79. INK4a and the control of cellular proliferative life span. Carcinogenesis, 20, 921-926.
80. Kim, Y.J. et al. (2009) Hepatitis B virus X protein overcomes stressinduced premature senescence by repressing p16(INK4a) expression via DNA methylation. Cancer Lett. doi:10.1016/j.canlet.2009.07.007.
81. Jacobs, J.J. et al. (1999) The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature, 397, 164-168.
82. Gil, J. et al. (2004) Polycomb CBX7 has a unifying role in cellular lifespan. Nat. Cell Biol., 6, 67-72.
83. Gonzalez, S. et al. (2006) A new mechanism of inactivation of the INK4/ARF locus. Cell Cycle, 5, 1382-1384.
84. Olovnikov, A.M. (1973) A theory of marginotomy. The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon. J. Theor. Biol., 41, 181-190.
85. Drayton, S. et al. (2002) Immortalisation and transformation revisited. Curr. Opin. Genet. Dev., 12, 98-104.
86. Lin, A.W. et al. (1998) Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev., 12, 3008-3019.
87. Satyanarayana, A. et al. (2004) Mitogen stimulation cooperates with telomere shortening to activate DNA damage responses and senescence signaling. Mol. Cell. Biol., 24, 5459-5474.
88. 2: senescence-like growth arrest or apoptosis? Cell Growth Differ., 8, 589-598.
89. Suzuki, T. et al. (2001) Induction of senescence-associated genes by 5-bromodeoxyuridine in HeLa cells. Exp. Gerontol., 36, 465-474.
90. Kim, K.S. et al. (2009) Interferon-γ induces cellular senescence through p53-dependent DNA damage signaling in human endothelial cells. Mech. Ageing Dev., 130, 179-188.
91. Kim, K.S. et al. (2007) Induction of cellular senescence by insulin-like growth factor binding protein-5 through a p53-dependent mechanism. Mol. Biol. Cell, 18, 4543-4552.
92. Matsumura, T. et al. (1989) Levels of DNA methylation in diploid and SV40 transformed human fibroblasts. Exp. Gerontol., 24, 477-481.
93. Howard, B.H. (1996) Replicative senescence: considerations relating to the stability of heterochromatin domains. Exp. Gerontol., 31, 281-293.
94. Watson, J.D. (1972) Origin of concatemeric T7 DNA. Nature New Biol., 239, 197-201.
95. Harley, C.B. et al. (1990) Telomeres shorten during ageing of human fibroblasts. Nature, 345, 458-460.
96. Levy, M.Z. et al. (1992) Telomere end-replication problem and cell aging. J. Mol. Biol., 225, 951-960.
97. Makarov, V.L. et al. (1997) Long G tails at both ends of human chromosomes suggest a C strand degradation mechanism for telomere shortening. Cell, 88, 657-666.
98. Rubelj, I. et al. (1999) Stochastic mechanism of cellular aging-abrupt telomere shortening as a model for stochastic nature of cellular aging. J. Theor. Biol., 197, 425-438.
99. Jiang, H. et al. (2007) Telomere shortening and ageing. Z. Gerontol. Geriatr., 40, 314-324.
100. Herbig, U. et al. (2004) Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21(CIP1), but not p16(INK4a). Mol. Cell, 14, 501-513.
101. Jacobs, J.J. et al. (2005) p16INK4a as a second effector of the telomere damage pathway. Cell Cycle, 4, 1364-1368.
102. Cohen, S.B. et al. (2007) Protein composition of catalytically active human telomerase from immortal cells. Science, 315, 1850-1853.
103. Venteicher, A.S. et al. (2009) A human telomerase holoenzyme protein required for Cajal body localization and telomere synthesis. Science, 323, 644-648.
104. Venteicher, A.S. et al. (2008) Identification of ATPases pontin and reptin as telomerase components essential for holoenzyme assembly. Cell, 132, 945-957.
105. Hoareau-Aveilla, C. et al. (2006) hNaf1 is required for accumulation of human box H/ACA snoRNPs, scaRNPs, and telomerase. RNA, 12, 832-840.
106. Dragon, F. et al. (2000) In vitro assembly of human H/ACA small nucleolar RNPs reveals unique features of U17 and telomerase RNAs. Mol. Cell. Biol., 20, 3037-3048.
107. Pogacic, V. et al. (2000) Human H/ACA small nucleolar RNPs and telomerase share evolutionarily conserved proteins NHP2 and NOP10. Mol. Cell. Biol., 20, 9028-9040.
108. Collins, K. et al. (2002) Telomerase in the human organism. Oncogene, 21, 564-579.
109. Bodnar, A.G. et al. (1998) Extension of life-span by introduction of telomerase into normal human cells. Science, 279, 349-352.
110. Vaziri, H. et al. (1998) Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr. Biol., 8, 279-282.
111. Cairney, C.J. et al. (2008) Telomerase redefined: integrated regulation of hTR and hTERT for telomere maintenance and telomerase activity. Biochimie, 90, 13-23.
112. Cao, Y. et al. (2008) Amplification of telomerase reverse transcriptase gene in human mammary epithelial cells with limiting telomerase RNA expression levels. Cancer Res., 68, 3115-3123.
113. Hathcock, K.S. et al. (2002) Haploinsufficiency of mTR results in defects in telomere elongation. Proc. Natl Acad. Sci. USA, 99, 3591-3596.
114. Armanios, M. (2009) Syndromes of telomere shortening. Annu. Rev. Genomics Hum. Genet., 10, 45-61.
115. Shay, J.W. et al. (1997) A survey of telomerase activity in human cancer. Eur. J. Cancer, 33, 787-791.
116. Cao, Y. et al. (2008) Increased copy number of the TERT and TERC telomerase subunit genes in cancer cells. Cancer Sci., 99, 1092-1099.
117. Blasco, M.A. (2002) Telomerase beyond telomeres. Nat. Rev. Cancer, 2, 627-633.
118. Broccoli, D. et al. (1996) Telomerase activation in mouse mammary tumors: lack of detectable telomere shortening and evidence for regulation of telomerase RNA with cell proliferation. Mol. Cell. Biol., 16, 3765-3772.
119. Cao, Y. et al. (2002) TERT regulates cell survival independent of telomerase enzymatic activity. Oncogene, 21, 3130-3138.
120. Sarin, K.Y. et al. (2005) Conditional telomerase induction causes proliferation of hair follicle stem cells. Nature, 436, 1048-1052.
121. Park, J.I. et al. (2009) Telomerase modulates Wnt signalling by association with target gene chromatin. Nature, 460, 66-72.
122. Reddel, R.R. et al. (2001) Alternative lengthening of telomeres in human cells. Radiat. Res., 155, 194-200.
123. Dunham, M.A. et al. (2000) Telomere maintenance by recombination in human cells. Nat. Genet., 26, 447-450.
124. Muntoni, A. et al. (2009) Telomere elongation involves intra-molecular DNA replication in cells utilizing Alternative Lengthening of Telomeres. Hum. Mol. Genet., 18, 1017-1027.
125. Henson, J.D. et al. (2009) Telomeric C-Circles provide a specific and quantitative assay for Alternative Lengthening of Telomeres activity. Nat. Biotechnol. doi:10.1038/nbt.1587.
126. Bailey, S.M. et al. (2004) Frequent recombination in telomeric DNA may extend the proliferative life of telomerase-negative cells. Nucleic Acids Res., 32, 3743-3751.
127. Muntoni, A. et al. (2005) The first molecular details of ALT in human tumor cells. Hum. Mol. Genet., 14 (suppl 2), R191-R196. 26
128. Londono-Vallejo, J.A. et al. (2004) Alternative lengthening of telomeres is characterized by high rates of telomeric exchange. Cancer Res., 64, 2324-2327.
129. Bryan, T.M. et al. (1995) Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J., 14, 4240-4248.
130. Tokutake, Y. et al. (1998) Extra-chromosome telomere repeat DNA in telomerase-negative immortalized cell lines. Biochem. Biophys. Res. Commun., 247, 765-772.
131. Ogino, H. et al. (1998) Release of telomeric DNA from chromosomes in immortal human cells lacking telomerase activity. Biochem. Biophys. Res. Commun., 248, 223-227.
132. Yeager, T.R. et al. (1999) Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res., 59, 4175-4179.
133. Wang, R.C. et al. (2004) Homologous recombination generates T-loopsized deletions at human telomeres. Cell, 119, 355-368.
134. Perrem, K. et al. (2001) Coexistence of alternative lengthening of telomeres and telomerase in hTERT-transfected GM847 cells. Mol. Cell. Biol., 21, 3862-3875.
135. Cesare, A.J. et al. (2009) Spontaneous occurrence of telomeric DNA damage response in the absence of chromosome fusions. Nat. Struct. Mol. Biol. doi: 10.1038/nsmb.1725.
136. Pickett, H.A. et al. (2009) Control of telomere length by a trimming mechanism that involves generation of t-circles. EMBO J., 28, 799-809.
137. Murnane, J.P. et al. (1994) Telomere dynamics in an immortal human cell line. EMBO J., 13, 4953-4962.
138. Bryan, T.M. et al. (1997) Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat. Med., 3, 1271-1274.
139. Henson, J.D. et al. (2005) A robust assay for alternative lengthening of telomeres (ALT) in tumors demonstrates the significance of ALT in sarcomas and astrocytomas. Clin. Cancer Res., 11, 217-225.
140. Reddel, R.R. et al. (2003) Alternative lengthening of telomeres: dangerous road less travelled. Lancet, 361, 1840-1841.
141. Hakin-Smith, V. et al. (2003) Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. Lancet, 361, 836-838.
142. Johnson, J.E. et al. (2005) Multiple mechanisms of telomere maintenance exist in liposarcomas. Clin. Cancer Res., 11, 5347-5355.
143. Costa, A. et al. (2006) Telomere maintenance mechanisms in liposarcomas: association with histologic subtypes and disease progression. Cancer Res., 66, 8918-8924.
144. Villa, R. et al. (2008) Multiple mechanisms of telomere maintenance exist and differentially affect clinical outcome in diffuse malignant peritoneal mesothelioma. Clin. Cancer Res., 14, 4134-4140.
145. Ulaner, G.A. et al. (2003) Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma. Cancer Res., 63, 1759-1763.
146. Subhawong, A.P. et al. (2009) The alternative lengthening of telomeres phenotype in breast carcinoma is associated with HER-2 overexpression. Mod. Pathol, 22, 1423-1431.
147. Lafferty-Whyte, K. et al. (2009) A gene expression signature classifying telomerase and ALT immortalization reveals an hTERT regulatory network and suggests a mesenchymal stem cell origin for ALT. Oncogene, 28, 3765-3774.
148. Henson, J.D. et al. (2002) Alternative lengthening of telomeres in mammalian cells. Oncogene, 21, 598-610.
149. Jiang, W.Q. et al. (2005) Suppression of alternative lengthening of telomeres by Sp100-mediated sequestration of MRE11/RAD50/NBS1 complex. Mol. Cell. Biol., 25, 2708-2721.
150. Zhong, Z.H. et al. (2007) Disruption of telomere maintenance by depletion of the MRE11/RAD50/NBS1 complex in cells that use alternative lengthening of telomeres. J. Biol. Chem., 282, 29314-29322.
151. Potts, P.R. et al. (2007) The SMC5/6 complex maintains telomere length in ALT cancer cells through SUMOylation of telomere-binding proteins. Nat. Struct. Mol. Biol., 14, 581-590.